LMI has been selected to support the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Logistics and Medical business area.
This 3-year task order was awarded under the Joint Enterprise-OMNIBUS Program, Engineering and Technical Support contract vehicle.
Since 2019, LMI has provided the JPEO-CBRND Logistics and Medical component technical, scientific and lifecycle management advisement for Food and Drug Administration-approved therapeutics, vaccines and diagnostics to combat CBRND threats.
“We are thrilled to extend our support and expertise by facilitating the successful technology transition, engineering development, and manufacturing of medical products in support of the critical JPEO-CBRND mission,” said Pete Pflugrath, LMI executive vice president of markets and growth.
With this task order, LMI’s bioengineers, scientists, clinical advisers, non-clinical advisers, regulatory affairs managers, quality assurance managers, process advisers, program logisticians and fielding coordinators will continue supporting the JPEO-CBRND Medical Countermeasure development mission.
“We are proud to work alongside government leaders and product developers to ensure the most effective CBRND capabilities are developed, manufactured, and delivered to the Joint Forces at the right time,” Pflugrath said.
The JPEO-CBRND manages the nation’s investments in CBRND equipment and medical countermeasures to support the joint force in developing and acquiring medical products to combat current and emerging threats.